Treating rheumatoid arthritis to target: the patient version of the international recommendations

To transcribe the treat-to-target (T2T) recommendations into a version that can be easily understood by patients. A core group of physicians and patients involved in the elaboration of the T2T recommendations produced a draft version of the T2T recommendations in lay language. This version was discussed, changed and reworded during a 1-day meeting with nine patients with rheumatoid arthritis (RA) from nine different European countries. Finally, the level of agreement with the translation and with the content of the recommendations was assessed by the patient participants. The project resulted in a patient version of the T2T recommendations. The level of agreement with the translation and the content was high. The group discussion revealed a number of potential barriers for the implementation of the recommendations in clinical practice, such as inequalities in arthritis healthcare provision across Europe. An accurate version of the T2T recommendations that can be easily understood by patients is available and can improve the shared decision process in the management of RA.

[1]  M. Boers,et al.  Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases , 2009, Annals of the rheumatic diseases.

[2]  D. M. van der Heijde,et al.  ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version , 2008, Annals of the rheumatic diseases.

[3]  S. Johnson,et al.  Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. , 2001, Annals of the rheumatic diseases.

[4]  P. Tugwell,et al.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice. , 2003, Rheumatology.

[5]  J. Weinman,et al.  Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. , 1999, Journal of psychosomatic research.

[6]  F. Guillemin,et al.  Compliance with drug therapy in rheumatoid arthritis. A longitudinal European study. , 2000, Joint, bone, spine : revue du rhumatisme.

[7]  J. Smolen,et al.  The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care. , 2009, Rheumatic diseases clinics of North America.

[8]  F Guillemin,et al.  EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees , 2004, Annals of the rheumatic diseases.

[9]  C. Allaart,et al.  Disease Activity Monitoring in Rheumatoid Arthritis in Daily Practice: Experiences with METEOR, a Free Online Tool , 2010, The Journal of Rheumatology.

[10]  M. Grunke,et al.  Information and participation in decision-making about treatment: a qualitative study of the perceptions and preferences of patients with rheumatoid arthritis , 2008, Journal of Medical Ethics.

[11]  J. Concato,et al.  Risk communication in rheumatoid arthritis. , 2003, Journal of Rheumatology.

[12]  A. Hammond,et al.  Need for information and for involvement in decision making among patients with rheumatoid arthritis: a questionnaire survey. , 2005, Arthritis and rheumatism.

[13]  P. van Riel,et al.  Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. , 1998, Arthritis and rheumatism.

[14]  David T Felson,et al.  UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .

[15]  M. Prevoo,et al.  Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. , 1996, British journal of rheumatology.

[16]  J. Concato,et al.  Unwillingness of rheumatoid arthritis patients to risk adverse effects. , 2002, Rheumatology.

[17]  A. Finset,et al.  Rheumatology care: Involvement in medical decisions, received information, satisfaction with care, and unmet health care needs in patients with rheumatoid arthritis and ankylosing spondylitis. , 2006, Arthritis and rheumatism.

[18]  M. Dougados,et al.  Extended report: Evidence for treating rheumatoid arthritis to target: results of a systematic literature search , 2010 .

[19]  M. Dougados,et al.  ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2005, Annals of the rheumatic diseases.

[20]  T. Pullar,et al.  The risk of treatment. A study of rheumatoid arthritis patients' attitudes. , 1998, British journal of rheumatology.

[21]  A. Cieza,et al.  Validation of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis from the patient perspective using focus groups , 2006, Arthritis research & therapy.

[22]  Maurizio Cutolo,et al.  Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.

[23]  A. Hammond,et al.  Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. , 2005, Rheumatology.

[24]  M. Boers,et al.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases , 2007, Annals of the rheumatic diseases.

[25]  J. Smolen,et al.  The definition and measurement of disease modification in inflammatory rheumatic diseases. , 2006, Rheumatic diseases clinics of North America.